Aim: The aim was to analyze the outcome of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy + adjuvant radiotherapy according to the risk groups and determine the adverse prognostic factors affecting survival in Hodgkin lymphoma.
Material and methods: A retrospective study was performed on 52 pediatric patients with Hodgkin lymphoma who were treated with ABVD between 1997 and 2018. Patients with early-stage favorable disease received 4 cycles of ABVD + radiotherapy. Early-stage unfavorable and advanced-stage patients received 6 cycles of ABVD + radiotherapy.
Results: Thirty (57.7%) boys and 22 (42.3%) girls were included in the study. The median age of the patients was 9 years and 3 months (1 year and 10 month 17 years and 7 months). Overall survival rate was 94.2% and the mean survival time was 19.5 ± 0.70 (95% CI, 18.1 - 20.9) years. The mean event-free survival time was 9.5 ± 6.5 years. Overall survival rate was 90%, and the mean event-free survival time was 8.2 ± 6.1 years in early-stage favorable disease. Overall survival rate was 100%, and the mean event-free survival time was 1.9 ± 7.0 years in early-stage unfavorable disease. Overall survival rate was 94.1 %, and the mean event-free survival time was 8.9 ± 6.3 years in advanced-stage disease. Presence of bulky disease, nodular sclerosing histologic subtype and leukocytosis had a negative prognostic effect on relapse and bulky disease had adverse effect on overall survival (p
Key words: Hodgkin lymphoma; prognosis; overall survival.
|
